KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Acadia Pharmaceuticals (ACAD) EBT: 2009-2025

Historic EBT for Acadia Pharmaceuticals (ACAD) over the last 17 years, with Sep 2025 value amounting to $44.6 million.

  • Acadia Pharmaceuticals' EBT rose 14.93% to $44.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $273.7 million, marking a year-over-year increase of 100.19%. This contributed to the annual value of $258.1 million for FY2024, which is 605.67% up from last year.
  • As of Q3 2025, Acadia Pharmaceuticals' EBT stood at $44.6 million, which was up 10.91% from $40.2 million recorded in Q2 2025.
  • Acadia Pharmaceuticals' EBT's 5-year high stood at $161.1 million during Q4 2024, with a 5-year trough of -$112.6 million in Q1 2022.
  • Its 3-year average for EBT is $29.1 million, with a median of $37.2 million in 2024.
  • Per our database at Business Quant, Acadia Pharmaceuticals' EBT slumped by 97.40% in 2023 and then skyrocketed by 486.47% in 2024.
  • Over the past 5 years, Acadia Pharmaceuticals' EBT (Quarterly) stood at -$42.9 million in 2021, then increased by 4.80% to -$40.8 million in 2022, then soared by 197.21% to $39.7 million in 2023, then spiked by 305.70% to $161.1 million in 2024, then rose by 14.93% to $44.6 million in 2025.
  • Its EBT was $44.6 million in Q3 2025, compared to $40.2 million in Q2 2025 and $27.8 million in Q1 2025.